Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.19M | 100.64M | 105.76M | 105.03M | 111.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.19M | 100.64M | 105.76M | 105.03M | 111.59M |
| Cost of Revenue | 4.18M | 3.80M | 3.88M | 3.96M | 4.18M |
| Gross Profit | 98.01M | 96.84M | 101.87M | 101.08M | 107.40M |
| SG&A Expenses | 75.66M | 73.48M | 73.62M | 77.82M | 75.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.85M | 90.21M | 89.53M | 94.66M | 92.68M |
| Operating Income | 9.34M | 10.43M | 16.23M | 10.38M | 18.91M |
| Income Before Tax | 11.58M | 15.37M | 23.22M | -77.83M | -70.57M |
| Income Tax Expenses | 2.84M | 3.68M | 5.32M | 5.82M | 8.42M |
| Earnings from Continuing Operations | 8.74 | 11.70 | 17.90 | -83.65 | -78.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.57M | -4.45M | -5.81M | -5.17M | -6.98M |
| Net Income | 4.17M | 7.25M | 12.09M | -88.82M | -85.97M |
| EBIT | 9.34M | 10.43M | 16.23M | 10.38M | 18.91M |
| EBITDA | 11.44M | 12.12M | 17.80M | 11.78M | 20.06M |
| EPS Basic | 0.05 | 0.08 | 0.14 | -1.25 | -1.20 |
| Normalized Basic EPS | 0.03 | 0.06 | 0.10 | -0.03 | 0.02 |
| EPS Diluted | 0.02 | 0.02 | 0.05 | -1.34 | -1.30 |
| Normalized Diluted EPS | 0.03 | 0.05 | 0.08 | -0.05 | 0.00 |
| Average Basic Shares Outstanding | 347.14M | 343.52M | 340.36M | 326.97M | 304.92M |
| Average Diluted Shares Outstanding | 393.27M | 392.77M | 393.39M | 380.00M | 356.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |